We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
- Authors
Hirbe, Angela C; Kaushal, Madhurima; Sharma, Mukesh Kumar; Dahiya, Sonika; Pekmezci, Melike; Perry, Arie; Gutmann, David H
- Abstract
<bold>Background: </bold>Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas that arise at an estimated frequency of 8% to 13% in individuals with neurofibromatosis type 1 (NF1). Compared with their sporadic counterparts, NF1-associated MPNSTs (NF1-MPNSTs) develop in young adults, frequently recur (approximately 50% of cases), and carry a dismal prognosis. As such, most individuals affected with NF1-MPNSTs die within 5 years of diagnosis, despite surgical resection combined with radiotherapy and chemotherapy.<bold>Methods: </bold>Clinical genomic profiling was performed using 1000 ng of DNA from 7 cases of NF1-MPNST, and bioinformatic analyses were conducted to identify genes with actionable mutations.<bold>Results: </bold>A total of 3 women and 4 men with NF1-MPNST were identified (median age, 38 years). Nonsynonymous mutations were discovered in 4 genes (neurofibromatosis type 1 [NF1], ROS proto-oncogene 1 [ROS1], tumor protein p53 [TP53], and tyrosine kinase 2 [TYK2]), which in addition were mutated in other MPNST cases in this sample set. Consistent with their occurrence in individuals with NF1, all tumors had at least 1 mutation in the NF1 gene. Whereas TP53 gene mutations are frequently observed in other cancers, ROS1 mutations are common in melanoma (15%-35%), another neural crest-derived malignancy. In contrast, TYK2 mutations are uncommon in other malignancies (<7%). In the current series, recurrent TYK2 mutations were identified in 2 cases of NF1-MPNST (30% of cases), whereas TYK2 protein overexpression was observed in 60% of MPNST cases using an independently generated tissue microarray, regardless of NF1 status.<bold>Conclusions: </bold>Clinical genomic analysis of the current series of NF1-MPNST cases found that TYK2 is a new gene mutated in MPNST. Future work will focus on examining the utility of TYK2 expression as a biomarker and therapeutic target for these cancers. Cancer 2017;123:1194-1201. © 2016 American Cancer Society.
- Subjects
AMINO acids; ANTHROPOMETRY; COMBINED modality therapy; GENE expression; IMMUNOHISTOCHEMISTRY; METASTASIS; GENETIC mutation; TRANSFERASES; NERVOUS system tumors; TISSUE arrays; GENE expression profiling; SEQUENCE analysis; DISEASE complications; NEUROFIBROMATOSIS 1; DIAGNOSIS; TUMOR treatment; THERAPEUTICS
- Publication
Cancer (0008543X), 2016, Vol 122, Issue 22, pN.PAG
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/cncr.30455